Hosted on MSN
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...
Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns, ...
Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback